SecBot SecBot
SECBOTREPLAY Home › Report › HCM

HCM · HUTCHMED announced positive Phase 3 results for sovleplenib in warm…

HUTCHMED (China) Limited · PRESS-RELEASE filed Jun 11, 2026 at 20:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 11, 2026 at 20:00 ET

HUTCHMED announced positive Phase 3 results for sovleplenib in warm AIHA (wAIHA), showing a 66% durable response rate vs 15% for placebo (p<0.0001). The NDA for wAIHA has been accepted and granted priority review by China's NMPA, and a separate resubmitted NDA for ITP also received priority review. These developments significantly strengthen sovleplenib's regulatory and commercial prospects in two indications with high unmet need.

  • Phase 3 ESLIM-02 study met primary endpoint: durable response rate 66% for sovleplenib vs 15% for placebo (p<0.0001) in wAIHA patients.
  • Overall response rate (Hb ≥100 g/L + ≥20 g/L increase without rescue) was 70% vs 22% (p<0.0001).
  • Rescue therapy use reduced to 16% (sovleplenib) vs 54% (placebo); RBC transfusions reduced to 11% vs 43%.
  • Median time to response was 3.1 weeks for sovleplenib vs 6.3 weeks for placebo.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access